AUM Biosciences Further Strengthens Advisory Board with Addition of Professor Peter E. Lobie
AUM Biosciences (AUM), a Singapore based company officially announced today the addition of Peter E. Lobie, M.D., Ph.D., tenured professor and Co-Director of the Precision Medicine and Healthcare Research Center in the Tsinghua-Berkeley Shenzhen Institute to its scientific advisory board (SAB). AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.
About Professor Peter E. Lobie
Professor Peter E. Lobie is Professor and Co-Director of the Precision Medicine and Healthcare Research Center in Tsinghua-Berkeley Shenzhen Institute (TBSI), which is jointly established by Tsinghua University and University of California, Berkeley under the support of the Shenzhen Municipal Government. The Precision Medicine and Healthcare Research Center aims to address key challenges and issues in global health by accelerating the transfer of knowledge and discoveries from basic research to translational medicine and clinical practice. The center, under Professor Lobie’s leadership, fosters an environment that encourages high-risk, high-reward innovative research and technology development in the fields of cancer, neurologic and cardiac diseases and regenerative medicine.
Prior to joining TBSI, Professor Lobie was Professor and Senior Principal Investigator at the Cancer Science Institute of Singapore. He has previously held faculty positions in Sweden, Singapore and New Zealand. He was also New Zealand’s first chair of Breast Cancer funded by the Breast Cancer Research Trust. Professor Lobie has been associated heavily with industry during his time in Sweden (Pharmacia), has consulted for Pfizer Inc. and Metabolic Inc. and in New Zealand served as a senior consultant to Neuren Pharmaceuticals and as head of their cancer research programme. He was the founding scientist of Perseis Therapeutics Ltd., and a founding shareholder in Wuhan Long Ke Ltd and Sinotar Therapeutics Ltd, two new entities focused on development of novel cancer target molecules. He is/was an editorial board member of Endocrinology and Molecular Endocrinology, among a number of other international journals and served on the Annual Meeting Steering Committee of The Endocrine Society (USA). He is a (co)-author on more than 170 papers and has served as a reviewer for more than 50 academic journals and more than 15 local and international granting agencies. Professor Lobie is the recipient of multiple local and international awards and has been appointed a Fellow (Academician) of the Royal Society of New Zealand. He was also awarded the Chinese Government Friendship Award, the highest honor given to foreigners from the People’s Republic of China.
Professor Lobie obtained a B.Med.Sci. (Distinction) and MBBS (Medicine First Class Honours) in 1992 from the University of Queensland in Australia. He was awarded the highest accolade from the University in the form of a University Medal. His postdoctoral work was undertaken at the Karolinska Institute in Sweden where he also obtained his doctoral degree (PhD).
“We are very fortunate and delighted to have Prof. Lobie join our SAB,” stated Dr. Harish Dave, CMO, AUM Biosciences. “His proficiency in precision medicine and understanding of Asian research scenario including China is directly applicable to AUM’s goal of identifying and developing candidates that suit our precision medicine mandate.”
“This is an exciting yet much needed venture. I look forward to interacting with AUM Biosciences to assist in their endeavor to provide novel but affordable cancer medicines to patients in Asia and globally” Prof. Peter Lobie stated.
About AUM Biosciences
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need. For more information, please visit www.aumbiosciences.com or firstname.lastname@example.org